​

Arcutis Biotherapeutics (ARQT) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

ARQT Stock Forecast

Arcutis Biotherapeutics (ARQT) stock forecast, based on 12 Wall Street analysts, predicts a 12-month average price target of $42.25, with a high of $48.00 and a low of $38.00. This represents a 31.21% increase from the last price of $32.20.

$20 $26 $32 $38 $44 $50 High: $48 Avg: $42.25 Low: $38 Last Closed Price: $32.2

ARQT Stock Rating

Arcutis Biotherapeutics stock's rating consensus is Buy, based on 12 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 10 Buy (83.33%), 2 Hold (16.67%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 12 2 10 0 Strong Sell Sell Hold Buy Strong Buy

ARQT Price Target Upside V Benchmarks

TypeNameUpside
StockArcutis Biotherapeutics31.21%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts3510
Avg Price Target$43.67$41.40$36.90
Last Closing Price$32.20$32.20$32.20
Upside/Downside35.62%28.57%14.60%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Oct, 26241--7
Sep, 26251--8
Aug, 26251--8
Jul, 26251--8
Jun, 26251--8
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 19, 2026Guggenheim$44.00$30.9842.03%36.65%
Oct 15, 2026Steve SeedhouseCantor Fitzgerald$48.00$26.4181.75%49.07%
Oct 08, 2026Kambiz YazdiJefferies$39.00$24.1761.36%21.12%
Aug 06, 2026Morgan Stanley$38.00$27.1040.22%18.01%
Aug 06, 2026Seamus FernandezGuggenheim$38.00$27.1040.22%18.01%
Feb 26, 2026Doug TsaoH.C. Wainwright$34.00$27.0125.88%5.59%
Nov 28, 2025Uy EarMizuho Securities$37.00$30.9619.51%14.91%
Oct 30, 2025Richard LawGoldman Sachs$29.00$25.4114.13%-9.94%
Oct 29, 2025Douglas TsaoH.C. Wainwright$30.00$24.9520.24%-6.83%
Oct 29, 2025Uy EarMizuho Securities$32.00$24.9528.26%-0.62%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Oct 19, 2026GuggenheimBuyBuyhold
Oct 15, 2026Cantor FitzgeraldOverweightinitialise
Oct 08, 2026JefferiesBuyBuyhold
Aug 06, 2026Morgan StanleyOverweightOverweighthold
Aug 06, 2026GuggenheimBuyBuyhold
Feb 26, 2026H.C. WainwrightBuyBuyhold
Oct 30, 2025Goldman SachsNeutralNeutralhold
Oct 29, 2025H.C. WainwrightBuyBuyhold
Aug 07, 2025Cowen & Co.BuyBuyhold
Mar 11, 2025JefferiesBuyBuyhold

Financial Forecast

EPS Forecast

$-7 $-5 $-3 $-1 $1 $3 $4 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-5.66$-3.78$-1.16$-0.13---
Avg Forecast$-5.93$-3.92$-1.32$-0.83$0.05$1.51$2.44
High Forecast$-4.99$-3.81$-1.18$-0.56$0.20$3.23$2.82
Low Forecast$-6.73$-4.02$-1.38$-0.96$-0.11$0.14$2.15
Surprise %-4.55%-3.57%-12.12%-84.34%---

Revenue Forecast

$0 $180M $360M $540M $720M $900M Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$3.69M$59.61M$196.54M$376.07M---
Avg Forecast$2.97M$57.58M$185.46M$288.65M$423.15M$635.90M$788.81M
High Forecast$3.28M$64.49M$190.80M$311.07M$427.21M$712.20M$883.44M
Low Forecast$2.61M$52.28M$181.24M$267.54M$419.09M$577.34M$716.17M
Surprise %23.99%3.52%5.97%30.29%---

Net Income Forecast

$-500M $-350M $-200M $-50M $100M $250M Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-311.46M$-262.14M$-140.04M$-16.14M---
Avg Forecast$-411.14M$-271.19M$-88.60M$-52.46M$3.08M$157.37M$168.97M
High Forecast$-345.49M$-263.71M$-81.47M$-38.68M$13.99M$223.66M$195.32M
Low Forecast$-466.18M$-278.68M$-95.73M$-66.23M$-7.84M$9.65M$148.74M
Surprise %-24.24%-3.34%58.05%-69.23%---

ARQT Forecast FAQ

Is Arcutis Biotherapeutics stock a buy?

Arcutis Biotherapeutics stock has a consensus rating of Buy, based on 12 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 10 Buy, 2 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Arcutis Biotherapeutics is a favorable investment for most analysts.

What is Arcutis Biotherapeutics's price target?

Arcutis Biotherapeutics's price target, set by 12 Wall Street analysts, averages $42.25 over the next 12 months. The price target range spans from $38 at the low end to $48 at the high end, suggesting a potential 31.21% change from the previous closing price of $32.2.

How does Arcutis Biotherapeutics stock forecast compare to its benchmarks?

Arcutis Biotherapeutics's stock forecast shows a 31.21% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Arcutis Biotherapeutics over the past three months?

  • October 2026: 28.57% Strong Buy, 57.14% Buy, 14.29% Hold, 0% Sell, 0% Strong Sell.
  • September 2026: 25.00% Strong Buy, 62.50% Buy, 12.50% Hold, 0% Sell, 0% Strong Sell.
  • August 2026: 25.00% Strong Buy, 62.50% Buy, 12.50% Hold, 0% Sell, 0% Strong Sell.

What is Arcutis Biotherapeutics’s EPS forecast?

Arcutis Biotherapeutics's average annual EPS forecast for its fiscal year ending in December 2026 is $0.05, marking a -138.46% decrease from the reported $-0.13 in 2025. Estimates for the following years are $1.51 in 2027, and $2.44 in 2028.

What is Arcutis Biotherapeutics’s revenue forecast?

Arcutis Biotherapeutics's average annual revenue forecast for its fiscal year ending in December 2026 is $423.15M, reflecting a 12.52% increase from the reported $376.07M in 2025. The forecast for 2027 is $635.9M, and $788.81M for 2028.

What is Arcutis Biotherapeutics’s net income forecast?

Arcutis Biotherapeutics's net income forecast for the fiscal year ending in December 2026 stands at $3.08M, representing a -119.07% decrease from the reported $-16.141M in 2025. Projections indicate $157.37M in 2027, and $168.97M in 2028.